Gujarat Themis Biosyn Files Audited Financial Statements for FY 2026
Gujarat Themis Biosyn Limited has filed its audited financial statements for the fiscal year ending March 31, 2026. The company confirmed that its financial statements provide a true and fair view. Key audit matters included revenue recognition and asset management. The company has met its CSR obligations for the period.
This is a standard annual financial reporting disclosure. While important for transparency, it does not introduce new strategic information or significant financial performance indicators that would drastically alter the company's valuation or market perception in the short term.
The announcement is a routine filing of audited financial statements and an auditor's report, which is a standard corporate compliance requirement. It does not contain any specific positive or negative news.
Gujarat Themis Biosyn Limited has submitted its audited financial statements for the financial year ended March 31, 2026. This submission follows a prior intimation on May 25, 2026, where the Board of Directors had approved these results. The detailed financial statements, along with the audit reports from the Statutory Auditor, have been enclosed and are also available on the company's website. These results are subject to adoption by the shareholders at the upcoming Annual General Meeting.
The Independent Auditor's Report confirms that the Ind AS financial statements provide a true and fair view of the company's financial position as of March 31, 2026, and its performance for the year ended on that date. Key audit matters highlighted include revenue recognition, capital work-in-progress/Property, Plant and Equipment (PPE), and provisions and contingent liabilities. The auditors have stated that the company has maintained proper books of accounts, and the financial statements are in agreement with these records. They also reported on the adequacy of internal financial controls over financial reporting. The report also detailed compliance with various sections of the Companies Act, 2013, including those related to loans, investments, deposits, cost records, statutory dues, and related party transactions. The company has also complied with its Corporate Social Responsibility (CSR) obligations, with ₹148.91 Lakhs transferred to a special account for ongoing projects for the financial year 2025-26.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under annual results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.